Objective To study the expressions of Eag1 and vascular endothelial growth factor (VEGF) in colorectal cancer,and to explore the relationships between Eagl and VEGF expressions and clinicopathologic features of colorectal cancer.The correlation between Eag1 and VEGF and their clinical significance in colorectal cancer were explored.Methods A total of 73 cases of colorectal cancer tissues,25 cases of colorectal adenoma and 10 cases of normal colorectal mucosa from January 2015 to December 2016 in Hunan Provincial People's Hospital were collected.The expressions of Eag1,VEGF protein and mRNA in 73 cases of colorectal cancer tissues,25 cases of colorectal adenoma and 10 cases of normal colorectal mucosa were detected by immunohistochemistry and real-time fluorescence quantitative polymerase chain reaction (RT-qPCR).The relationships between the two factors and the clinical pathological features of patients with colorectal cancer were analyzed.Results Immunohistochemistry showed that the positive rate of Eag1 in colorectal cancer group was 86.30％ (63/73),which was significantly higher than that in colorectal adenoma group (20.00％,5/25) and normal colorectal mucosa group (10.00％,1/10),with significant differences (x2 =38.539,P ＜0.001;x2 =24.874,P ＜ 0.001).The positive rate of VEGF in colorectal cancer group was 89.04％ (65/73),which was significantly higher thah that in colorectal adenoma group (56.00％,14/25) and normal colorectal mucosa group (30.00％,3/10),with significant differences (x2 =10.980,P ＜0.001;x2 =16.911,P ＜0.001).There was a significant positive correlation between Eag1 and VEGF in colorectal cancer and colorectal adenoma tissues (c =0.580,P =0.010;c =0.669,P ＜ 0.001).The results of RT-qPCR showed that the expressions of Eag1 and VEGF mRNA in colorectal cancer group,colorectal adenoma group and normal colorectal mucosa group were 4.50 ±0.34,3.14 ±0.44;1.42 ±0.22,1.61 ±0.15 and 1.00 ±0.16,1.00 ±0.53,respectively,and the differences were statistically significant (F =15.546,P =0.014;F =5.363,P =0.025).The relative expression levels of Eag1 and VEGF mRNA in colorectal cancer group was about 4.50 times (t =31.851,P =0.003) and 3.14 times (t =6.870,P =0.014) than those in normal colorectal mucosa group.The mRNA expression levels of Eag1 and VEGF in colorectal cancer were correlated with degree of differentiation (F =840.725,P ＜ 0.001;F =102.950,P ＜ 0.001),depth of invasion (t =4.754,P ＜ 0.001;t =8.557,P ＜0.001),Duke staging (F =179.902,P ＜ 0.001;F =55.911,P ＜ 0.001) and lymph node metastasis (t =20.337,P ＜ 0.001;t =25.218,P ＜ 0.001).But they were not related to age (t =0.196,P =0.845;t =0.534,P =0.595) and sex (t =0.409,P =0.684;t =1.078,P =0.285).Conclusion Eag1 and VEGF are highly expressed in colorectal cancer tissues with positive correlation,and are closely related to the degree of differentiation,depth of invasion,Duke staging and lymph node metastasis of colorectal cancer.Both of them play important roles in the occurrence and development of colorectal cancer,which is expected to provide favorable research directions to the early diagnosis,treatment and prognosis of colorectal cancer.

Objective To investigate the application effects of the new restraint tools in the critical patient care. Methods A total of 354 critical patients were averagely divided into observation group and control group according to the order number with random number table. The patients in the control group were routinely used ordinary restraint belt with restraint upper limbs or limbs, while the patients underwent the new restraint tools and implemented personalized restraint that emphasize personalized and humanized on restraint of method, site, time and tools selecting. Results In the observation group, binding site skin abnormalities ( swelling, bruising or injury), unplanned extubation rates were lower than these of the control group (P <0. 05). Conclusions Personalized application of the new restraint tool can reduce restraint adverse events, ensure patient safety and improve effectiveness of care and safety management.